Anti-Xa based dosing of enoxaparin in hematopoietic stem cell transplant and adoptive cell therapy patients: A single center experience.

• Hematopoietic stem cell transplant and adoptive cellular therapies put patients at risk of clotting and bleeding. • In a retrospective cohort of patients receiving enoxaparin, anti-Xa based dosing resulted in decreased doses of enoxaparin. • Large randomized studies are needed to demonstrate the utility of anti-Xa monitoring in this unique patient population. [ABSTRACT FROM AUTHOR]